Alnylam announces publication of preclinical results based on novel conjugate technology that facilitates delivery of short interfering rna to the central nervous system and other extrahepatic tissues

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, announced today that data from its preclinical research on delivery of lipophilic short interfering rna (sirna) conjugates to extra-hepatic tissues, including the central nervous system (cns), were published online in nature biotechnology. the published data provide early evidence of a potential role for 2'-o-hexadecyl (c16)-conjugated sirnas in treating diseases of the cns, e
ALNY Ratings Summary
ALNY Quant Ranking